Ishara Investments LP is an SEC-registered investment adviser based in Los Angeles, CA that reports managing 1 hedge fund on Form ADV. It reports $259.1 million in regulatory assets under management. Its private funds, of all types, hold $19.9 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +22.9% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +22.9% from Q1 2026 to Q2 2026, compared with +9.5% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $259.1 millionForm ADV Item 5.F
- Gross assets of private funds
- $19.9 millionAll private fund types, Form ADV
- Hedge funds managed
- 11 private funds in total
- Employees
- 6Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 331869
- Latest Form ADV
- 03/19/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +20.8% | +14.8% |
| Q1 2026 | +1.7% | -4.6% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 40 share positions ($119,503,810) reported by Ishara Investments LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Travere Therapeutics Inc7.14%
- Cytokinetics Inc7.06%
- Bridgebio Pharma Inc5.51%
- Acadia Pharmaceuticals Inc5.40%
- Tarsus Pharmaceuticals Inc4.60%
- PTC Therapeutics Inc4.34%
- Praxis Precision Medicines I4.14%
- Vera Therapeutics Inc4.05%
- Arcutis Biotherapeutics Inc3.98%
- Annexon Inc3.96%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Travere Therapeutics Inc | $8,537,600 | 7.14% | 145,000 | +76.83% |
| Cytokinetics Inc | $8,436,480 | 7.06% | 128,000 | +290.24% |
| Bridgebio Pharma Inc | $6,580,000 | 5.51% | 100,000 | +74.22% |
| Acadia Pharmaceuticals Inc | $6,448,000 | 5.40% | 320,000 | -21.95% |
| Tarsus Pharmaceuticals Inc | $5,502,700 | 4.60% | 70,000 | New |
| PTC Therapeutics Inc | $5,182,400 | 4.34% | 80,000 | New |
| Praxis Precision Medicines I | $4,950,910 | 4.14% | 17,000 | -24.61% |
| Vera Therapeutics Inc | $4,843,500 | 4.05% | 150,000 | +1,363.41% |
| Arcutis Biotherapeutics Inc | $4,757,400 | 3.98% | 180,000 | New |
| Annexon Inc | $4,737,600 | 3.96% | 1,120,000 | +36.59% |
| United Therapeutics Corp Del | $4,335,120 | 3.63% | 8,000 | New |
| Newamsterdam Pharma Company | $3,891,200 | 3.26% | 160,000 | +333.60% |
| Xeris Biopharma Holdings Inc | $3,824,000 | 3.20% | 400,000 | -67.48% |
| Celcuity Inc | $3,816,960 | 3.19% | 48,000 | New |
| DBV Technologies S A | $3,175,200 | 2.66% | 270,000 | +46.34% |
| Viridian Therapeutics Inc | $3,088,500 | 2.58% | 150,000 | New |
| Zentalis Pharmaceuticals Inc | $2,991,600 | 2.50% | 1,080,000 | +5.37% |
| Biomarin Pharmaceutical Inc | $2,880,000 | 2.41% | 48,000 | -66.55% |
| Biogen Inc | $2,710,560 | 2.27% | 12,000 | New |
| Mineralys Therapeutics Inc | $2,513,000 | 2.10% | 100,000 | -2.44% |
| Ligand Pharmaceuticals Inc | $2,498,960 | 2.09% | 8,000 | New |
| Ultragenyx Pharmaceutical In | $2,404,800 | 2.01% | 160,000 | -21.95% |
| Vaxcyte Inc | $2,276,000 | 1.90% | 40,000 | -51.22% |
| Oric Pharmaceuticals Inc | $2,155,200 | 1.80% | 160,000 | +30.08% |
| Axsome Therapeutics Inc. | $1,843,900 | 1.54% | 10,000 | -39.02% |
| Silence Therapeutics PLC | $1,748,800 | 1.46% | 160,000 | -3.64% |
| Beam Therapeutics Inc | $1,711,500 | 1.43% | 70,000 | +70.73% |
| Biohaven LTD | $1,602,000 | 1.34% | 120,000 | New |
| Contineum Therapeutics Inc | $1,449,360 | 1.21% | 108,000 | -47.32% |
| Genmab A/s | $1,427,000 | 1.19% | 40,000 | -60.98% |
| Neurocrine Biosciences Inc | $1,134,720 | 0.95% | 8,000 | New |
| Monopar Therapeutics Inc | $956,040 | 0.80% | 12,000 | -2.44% |
| Moonlake Immunotherapeutics | $936,000 | 0.78% | 80,000 | New |
| Ars Pharmaceuticals Inc | $862,000 | 0.72% | 200,000 | -7.08% |
| Ionis Pharmaceuticals Inc | $714,400 | 0.60% | 16,000 | New |
| Olema Pharmaceuticals Inc | $691,200 | 0.58% | 80,000 | New |
| Lexicon Pharmaceuticals Inc | $600,000 | 0.50% | 320,000 | -74.82% |
| Wave Life Sciences Inc. | $592,000 | 0.50% | 160,000 | New |
| Savara Inc | $412,800 | 0.35% | 80,000 | New |
| Gossamer Bio Inc | $284,400 | 0.24% | 24,000 | New |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 16 new positions, 17 sold out, 10 increased, 14 reduced and 0 unchanged.
Number of positions (a count, not dollars)
- New positions16
- Increased10
- Unchanged0
- Reduced14
- Sold out17
New positions
| Stock | Value | Shares |
|---|---|---|
| Tarsus Pharmaceuticals Inc | $5,502,700 | 70,000 |
| PTC Therapeutics Inc | $5,182,400 | 80,000 |
| Arcutis Biotherapeutics Inc | $4,757,400 | 180,000 |
| United Therapeutics Corp Del | $4,335,120 | 8,000 |
| Celcuity Inc | $3,816,960 | 48,000 |
| Viridian Therapeutics Inc | $3,088,500 | 150,000 |
| Biogen Inc | $2,710,560 | 12,000 |
| Ligand Pharmaceuticals Inc | $2,498,960 | 8,000 |
| Biohaven LTD | $1,602,000 | 120,000 |
| Neurocrine Biosciences Inc | $1,134,720 | 8,000 |
| Moonlake Immunotherapeutics | $936,000 | 80,000 |
| Ionis Pharmaceuticals Inc | $714,400 | 16,000 |
| Olema Pharmaceuticals Inc | $691,200 | 80,000 |
| Wave Life Sciences Inc. | $592,000 | 160,000 |
| Savara Inc | $412,800 | 80,000 |
| Gossamer Bio Inc | $284,400 | 24,000 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Agios Pharmaceuticals Inc | $6,086,040 | 164,000 |
| Insmed Inc | $5,464,275 | 51,250 |
| Crinetics Pharmaceuticals In | $5,369,770 | 143,500 |
| Tonix Pharmaceuticals Hldg C | $4,316,070 | 338,250 |
| Kura Oncology Inc | $3,035,948 | 276,750 |
| Nuvation Bio Inc | $2,095,920 | 369,000 |
| Wave Life Sciences LTD | $1,905,680 | 328,000 |
| Nektar Therapeutics | $1,860,437 | 26,650 |
| Scholar Rock Hldg Corp | $1,691,250 | 30,750 |
| Enliven Therapeutics Inc | $1,664,600 | 32,800 |
| Alnylam Pharmaceuticals Inc | $1,542,779 | 5,125 |
| Sionna Therapeutics Inc | $1,350,540 | 123,000 |
| Vertex Pharmaceuticals Inc | $1,221,956 | 2,460 |
| Erasca Inc | $751,120 | 41,000 |
| Immatics N.V | $311,498 | 30,750 |
| Mereo Biopharma Group PLC | $244,232 | 768,750 |
| Gossamer Bio Inc | $134,972 | 820,000 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Cytokinetics Inc | +95,200 | +290.24% | $8,436,480 | 128,000 |
| Vera Therapeutics Inc | +139,750 | +1,363.41% | $4,843,500 | 150,000 |
| Travere Therapeutics Inc | +63,000 | +76.83% | $8,537,600 | 145,000 |
| Newamsterdam Pharma Company | +123,100 | +333.60% | $3,891,200 | 160,000 |
| Bridgebio Pharma Inc | +42,600 | +74.22% | $6,580,000 | 100,000 |
| Annexon Inc | +300,000 | +36.59% | $4,737,600 | 1,120,000 |
| DBV Technologies S A | +85,500 | +46.34% | $3,175,200 | 270,000 |
| Beam Therapeutics Inc | +29,000 | +70.73% | $1,711,500 | 70,000 |
| Oric Pharmaceuticals Inc | +37,000 | +30.08% | $2,155,200 | 160,000 |
| Zentalis Pharmaceuticals Inc | +55,000 | +5.37% | $2,991,600 | 1,080,000 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Xeris Biopharma Holdings Inc | -830,000 | -67.48% | $3,824,000 | 400,000 |
| Biomarin Pharmaceutical Inc | -95,500 | -66.55% | $2,880,000 | 48,000 |
| Vaxcyte Inc | -42,000 | -51.22% | $2,276,000 | 40,000 |
| Genmab A/s | -62,500 | -60.98% | $1,427,000 | 40,000 |
| Acadia Pharmaceuticals Inc | -90,000 | -21.95% | $6,448,000 | 320,000 |
| Lexicon Pharmaceuticals Inc | -951,000 | -74.82% | $600,000 | 320,000 |
| Praxis Precision Medicines I | -5,550 | -24.61% | $4,950,910 | 17,000 |
| Contineum Therapeutics Inc | -97,000 | -47.32% | $1,449,360 | 108,000 |
| Axsome Therapeutics Inc. | -6,400 | -39.02% | $1,843,900 | 10,000 |
| Ultragenyx Pharmaceutical In | -45,000 | -21.95% | $2,404,800 | 160,000 |
| Silence Therapeutics PLC | -6,050 | -3.64% | $1,748,800 | 160,000 |
| Ars Pharmaceuticals Inc | -15,235 | -7.08% | $862,000 | 200,000 |
| Mineralys Therapeutics Inc | -2,500 | -2.44% | $2,513,000 | 100,000 |
| Monopar Therapeutics Inc | -300 | -2.44% | $956,040 | 12,000 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Hedge funds filing Form D (1)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures